StockNews.com Initiates Coverage on IRIDEX (NASDAQ:IRIX)

StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX) in a report issued on Wednesday morning. The firm issued a hold rating on the medical equipment provider’s stock.

IRIDEX Price Performance

Shares of NASDAQ IRIX opened at $1.61 on Wednesday. The company has a market capitalization of $26.79 million, a PE ratio of -2.40 and a beta of 0.84. The company has a quick ratio of 0.85, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. The stock’s 50 day moving average price is $1.70 and its 200-day moving average price is $1.76. IRIDEX has a twelve month low of $1.27 and a twelve month high of $3.65.

IRIDEX (NASDAQ:IRIX) last issued its earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share for the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. The business had revenue of $11.58 million for the quarter. During the same period in the previous year, the company earned ($0.11) EPS.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.